Research Analysts Issue Forecasts for TSE:GUD Q4 Earnings

Knight Therapeutics Inc. (TSE:GUD) – Raymond James issued their Q4 2025 earnings estimates for Knight Therapeutics in a research report issued on Thursday, March 20th. Raymond James analyst M. Freeman anticipates that the company will post earnings of $0.01 per share for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Raymond James also issued estimates for Knight Therapeutics’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at $0.04 EPS.

Separately, Research Capitl upgraded shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th.

Knight Therapeutics Price Performance

Shares of GUD stock opened at C$6.18 on Monday. The company has a market capitalization of C$625.11 million, a PE ratio of -20.63, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The firm has a fifty day simple moving average of C$5.68 and a 200-day simple moving average of C$5.58. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52. Knight Therapeutics has a twelve month low of C$5.09 and a twelve month high of C$6.45.

Insider Activity

In related news, insider Sime Armoyan purchased 17,600 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average cost of C$5.48 per share, with a total value of C$96,488.48. Over the last three months, insiders sold 643,300 shares of company stock worth $3,983,740. 45.62% of the stock is currently owned by company insiders.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.